390 related articles for article (PubMed ID: 12627729)
21. Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate.
Huang YS; Guilleminault C
Pediatr Neurol; 2009 Jul; 41(1):9-16. PubMed ID: 19520267
[TBL] [Abstract][Full Text] [Related]
22. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
Black J; Swick T; Bogan R; Lai C; Carter LP
Sleep Med; 2016 Aug; 24():57-62. PubMed ID: 27810187
[TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients.
Borgen LA; Okerholm RA; Lai A; Scharf MB
J Clin Pharmacol; 2004 Mar; 44(3):253-7. PubMed ID: 14973300
[TBL] [Abstract][Full Text] [Related]
24. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.
Lecendreux M; Plazzi G; Dauvilliers Y; Rosen CL; Ruoff C; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
J Clin Sleep Med; 2022 Sep; 18(9):2217-2227. PubMed ID: 35689598
[TBL] [Abstract][Full Text] [Related]
25. Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy.
Owen RT
Drugs Today (Barc); 2008 Mar; 44(3):197-204. PubMed ID: 18536781
[TBL] [Abstract][Full Text] [Related]
26. [Integrated treatment of the symptoms of narcolepsy-cataplexy syndrome with sodium oxybate].
Poza-Aldea JJ
Rev Neurol; 2009 Jan 1-15; 48(1):27-31. PubMed ID: 19145563
[TBL] [Abstract][Full Text] [Related]
27. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.
Kushida CA; Shapiro CM; Roth T; Thorpy MJ; Corser BC; Ajayi AO; Rosenberg R; Roy A; Seiden D; Dubow J; Dauvilliers Y
Sleep; 2022 Jun; 45(6):. PubMed ID: 34358324
[TBL] [Abstract][Full Text] [Related]
28. The use of sodium oxybate to treat narcolepsy.
Mayer G
Expert Rev Neurother; 2012 May; 12(5):519-29. PubMed ID: 22550980
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.
Bogan RK; Thorpy MJ; Dauvilliers Y; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Tang L; Skobieranda F; Šonka K
Sleep; 2021 Mar; 44(3):. PubMed ID: 33184650
[TBL] [Abstract][Full Text] [Related]
30. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial.
Russell IJ; Perkins AT; Michalek JE;
Arthritis Rheum; 2009 Jan; 60(1):299-309. PubMed ID: 19116896
[TBL] [Abstract][Full Text] [Related]
31. Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate.
Murali H; Kotagal S
Sleep; 2006 Aug; 29(8):1025-9. PubMed ID: 16944670
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial.
Dauvilliers Y; Roth T; Bogan R; Thorpy MJ; Morse AM; Roy A; Dubow J; Gudeman J
Sleep; 2023 Nov; 46(11):. PubMed ID: 37246913
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
Bogan RK; Foldvary-Schaefer N; Skowronski R; Chen A; Thorpy MJ
CNS Drugs; 2023 Apr; 37(4):323-335. PubMed ID: 36947322
[TBL] [Abstract][Full Text] [Related]
34. Sodium oxybate for excessive daytime sleepiness in narcolepsy-cataplexy.
Arnulf I; Mignot E
Sleep; 2004 Nov; 27(7):1242-3. PubMed ID: 15586777
[No Abstract] [Full Text] [Related]
35. Weight loss in narcolepsy patients treated with sodium oxybate.
Husain AM; Ristanovic RK; Bogan RK
Sleep Med; 2009 Jun; 10(6):661-3. PubMed ID: 19014899
[TBL] [Abstract][Full Text] [Related]
36. Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary.
Roth T; Thorpy MJ; Kushida CA; Horsnell M; Gudeman J
J Comp Eff Res; 2023 Dec; 12(12):e230133. PubMed ID: 37971303
[TBL] [Abstract][Full Text] [Related]
37. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy.
Scharf MB; Brown D; Woods M; Brown L; Hirschowitz J
J Clin Psychiatry; 1985 Jun; 46(6):222-5. PubMed ID: 3888969
[TBL] [Abstract][Full Text] [Related]
38. Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.
Dauvilliers Y; Šonka K; Bogan RK; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Chen A; Black J; Skobieranda F; Thorpy MJ
CNS Drugs; 2022 Jun; 36(6):633-647. PubMed ID: 35635687
[TBL] [Abstract][Full Text] [Related]
39. Sodium oxybate in narcolepsy with cataplexy: Zurich sleep center experience.
Poryazova R; Tartarotti S; Khatami R; Baumann CR; Valko P; Kallweit U; Werth E; Bassetti CL
Eur Neurol; 2011; 65(3):175-82. PubMed ID: 21389728
[TBL] [Abstract][Full Text] [Related]
40. EFNS guidelines on management of narcolepsy.
Billiard M; Bassetti C; Dauvilliers Y; Dolenc-Groselj L; Lammers GJ; Mayer G; Pollmächer T; Reading P; Sonka K;
Eur J Neurol; 2006 Oct; 13(10):1035-48. PubMed ID: 16987156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
